Job Opening: Research Scientist, CAR-NK Cells

//Job Opening: Research Scientist, CAR-NK Cells

Description

Poseida Therapeutics, Inc. is seeking an outstanding candidate to join our immuno-oncology team at San Diego, CA. The Scientist will have a detailed knowledge of Natural Killer (NK) cell signaling, NK cell therapies, and tumor immunology.  Expertise in the culture, manipulation, and characterization of NK cells expressing anti-tumor effects is critical. The successful candidate will primarily perform experiments for the development of cellular therapies against cancer using NK, among others. Additionally, experience with chimeric antigen receptors (CARs) and/or NK cell allotransplant is a plus. The role includes developing and optimizing methodologies and assays as well as planning, executing, interpreting, and troubleshooting experiments using good scientific judgment. The scientist will demonstrate excellent oral and written communication skills, work well independently and as part of a team, and be able to work on multiple projects simultaneously. The position is a hands-on, laboratory-based role with the possibility of direct reports.

Poseida is currently developing CAR-T and gene therapy products for cancer and orphan diseases. Poseida is a pre-IPO company with $30M in Series A financing and is currently partnered with J&J’s Janssen to develop allogeneic CAR-T therapies against cancer. Poseida has entered into a worldwide License Agreement with Janssen to research, develop, manufacture and commercialize licensed products using Janssen Centyrin technology. Centyrins are non-scFv, alternative binders that are fully human and one fifth the size of a traditional scFv. In addition, Poseida boasts best-in-class genome engineering capabilities for stable transgene integration or targeted gene disruption. Proprietary tools include piggyBac™ DNA Modification System (capable of delivering 300kb+ of cargo for stable integration and long-term expression), Footprint-Free™ Gene Editing System, NextGEN™ CRISPR, and XTN™ TALEN, which are synthetic, non-viral, and can be surgically precise. Poseida aims to advance the first CAR-T product against multiple myeloma and gene therapy product against Progressive Familial Intraheptic Cholestasis 3. Please visit www.poseida.com for more information.

Qualifications
Required Experience and Skills:

  • PhD or equivalent in immunology, molecular biology, or related field and ≥ 2 years of experience in the field
  • A detailed knowledge of NK cell therapies, allotransplant, and tumor immunology
  • Expertise in the culture, manipulation, and characterization of anti-tumor NK
  • A strong understanding of cellular and/or tumor immunology principles, technologies, and experimental techniques (cell culture, in vitro cellular assays, flow cytometry, etc…)
  • Multi-parameter flow cytometry and proficiency in FACS data analysis programs
  • Molecular biology, Cloning and PCR technologies, genetic manipulation
  • Demonstrated track record in successfully developing and employing in vitro/in vivo models
  • Ability to organize, communicate, and present complex data sets to key stakeholders from diverse backgrounds
  • Excellent oral and communication skills

Preferred Experience and Skills:

  • Experience developing, testing, and/or utilizing CARs is a plus
  • Ex vivo NK cell expansion and/or NK cell allotransplant
  • Electroporation techniques and technologies (Plasmid DNA, RNA)
  • Viral vector design and transduction techniques (retroviral, lentiviral)
  • Cell separation technologies (e.g., Miltenyi AutoMACS) and FACS sorting
  • Genetic manipulation using CRISPRs, TALENs, or ZFNs
  • Expertise in the culture, manipulation, and characterization of anti-tumor CIK cells
  • Murine tumor models (genetically engineered or syngeneic)
  • Work with external academic, biotechnology, and contract research organizations
  • Mentor and guide other scientists in the group as needed
  • Previous supervisory skills